An observational study in Carcinoma, Renal Cell Carcinoma and RCC, sponsored by Jinling Hospital, China. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Jinling Hospital, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.
Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 16th largest by planned enrollment of the 45 observational ones that give a count, is one of 22 that started in 2022, is one of 45 observational ones, reaches primary completion later than 116 of the 141 other live ones, and was the 115th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:
Norroy Bioscience Co., LTD · Sites in China
Ages 18+
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
Hangzhou Huasai Biomedicine Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
235 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 93 · Phase 3 23 · Phase 4 1
First in 2005; this study’s year is marked. 22 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 66 across the 190 interventional studies, 300 across the 45 observational. Of the 58 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 235 have an industry lead sponsor. The 10 most frequent:
Jinling Hospital, China is the lead sponsor of 131 studies on the registry; 35 are open to participants now.
Jinling Hospital, China has 9 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
36 of the studies in Carcinoma, Renal Cell with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT07881900Phase 3Sun Yat-sen UniversityBenmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma | 2027-06-30 |
| NCT06680089RenJi HospitalCD70-targeted immunoPET Imaging of Kidney Cancer | 2026-11 |
| NCT050242143D Medicines (Sichuan) Co., Ltd.Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | 2026-12 |
| NCT06852638RenJi HospitalCD70-targeted immunoPET Imaging of Malignant Cancers | 2026-12-23 |
Add all 36 to your calendar (.ics) → With an account.
Among the 235 studies in Carcinoma, Renal Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
Some studies have shown the potential of ctDNA in renal cancer monitoring, but the amount of ctDNA released in renal cancer is the lowest among non-cranial tumors. Even in advanced patients, the detection rate of tumor system mutation is less than 50%. DNA methylation is important in the process of tumor occurrence and development. However, no studies have focused on the value of ctDNA methylation in monitoring renal cancer, nor have large prospective cohort studies been conducted in patients with renal cancer.
This study intended to analyze the dynamic changes of circulating tumor DNA and its methylation status in patients with kidney cancer from preoperative to long-term follow-up, and to compare the evaluation value of methylation detection with traditional imaging examination and traditional blood tumor markers in the monitoring process.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
This study's planned enrollment of 450 is above the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Browse Carcinoma, Renal Cell studies →Jinling Hospital, China is the lead sponsor of 131 studies on the registry; 35 are open to participants now.
Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
RCC patients undergoing surgical treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To explore the predictive effect of ctDNA methylomics on the prognosis and medication guidance of renal carcinoma.
Time frame: 5 years
To explore the advance time of ctDNA methylomics in monitoring postoperative recurrence of renal cancer compared with imaging.
Time frame: 5 years
The molecular mechanism of renal cancer recurrence was analyzed with baseline tissue and circulating methylation profiles.
Time frame: 5 years
A renal cancer recurrence risk model was established based on clinical information, molecular risk factors and ctDNA methylomics
Time frame: 5 years
Started Dec 2022 (actual). Primary completion is estimated for Jun 2028, 66 months after the start.
Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's planned 66 months is above that.
Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.